It is now well documented that M-CLL is associated with superior prognosis in CLL compared to U-CLL (Agathangelidis et al. 2022). Now data are accumulating to suggest that CD180 could be useful as a prognostic biomarker in different diseases. This evidence concerns the gene CD180 and B-cell chronic lymphocytic leukemia.